MorphoSys Recognized as Technology Pioneer 2009 by the World Economic Forum

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that the Company has been recognized by the World Economic
Forum as a Technology Pioneer 2009. The World Economic Forum has
selected 34 companies out of more than 320 applications from 15
countries for their accomplishments as innovators, and their work's
current and future impact on business and society.

The Technology Pioneers program of the Forum aims to recognize
companies that have contributed to the Forum's mission of improving
the state of the world and are at the forefront of technology and
innovation. To be selected as a Technology Pioneer, a company must
be involved in the development of life-changing technology innovation
and have the potential for long-term impact on business and society.
In addition, it must demonstrate visionary leadership and show all
the signs of being a long-standing market leader - and its technology
must be proven.

"We congratulate the 34 newly selected Technology Pioneers for their
remarkable achievements and welcome them to the wider community of
the World Economic Forum. During these difficult times, we are
certain that the technologies driven by these visionary companies
will contribute to the next wave of growth, with the innovative and
entrepreneurial spirit that characterizes them," said André
Schneider, Managing Director and Chief Operating Officer of the World
Economic Forum.

For more information please visit the official website of the World
Economic Forum:
http://www.weforum.org/en/Communities/Technology%20Pioneers/index.htm.

For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj,
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com

About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, RapMAT® and HuCAL PLATINUM® are registered
trademarks of MorphoSys AG

This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2008. All rights reserved.